This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Editorial

. 2011 Nov;37(11):1721-2.

doi: 10.1007/s00134-011-2330-1. Epub 2011 Aug 17.

Gut mucosal permeability, β1 receptor blockers and gastric tonometry: the time is now!

Guillermo Gutierrez, Guillermo Ballarino

PMID: 21847650
DOI: 10.1007/s00134-011-2330-1

Editorial

Gut mucosal permeability, β1 receptor blockers and gastric tonometry: the time is now!

Guillermo Gutierrez et al. Intensive Care Med. 2011 Nov.

. 2011 Nov;37(11):1721-2.

doi: 10.1007/s00134-011-2330-1. Epub 2011 Aug 17.

Authors

Guillermo Gutierrez, Guillermo Ballarino

PMID: 21847650
DOI: 10.1007/s00134-011-2330-1

No abstract available

PubMed Disclaimer

Comment on

Beta-1 blocker improves survival of septic rats through preservation of gut barrier function.
Mori K, Morisaki H, Yajima S, Suzuki T, Ishikawa A, Nakamura N, Innami Y, Takeda J. Mori K, et al. Intensive Care Med. 2011 Nov;37(11):1849-56. doi: 10.1007/s00134-011-2326-x. Epub 2011 Aug 17. Intensive Care Med. 2011. PMID: 21847651

Similar articles

Beta-1 blocker improves survival of septic rats through preservation of gut barrier function.
Mori K, Morisaki H, Yajima S, Suzuki T, Ishikawa A, Nakamura N, Innami Y, Takeda J. Mori K, et al. Intensive Care Med. 2011 Nov;37(11):1849-56. doi: 10.1007/s00134-011-2326-x. Epub 2011 Aug 17. Intensive Care Med. 2011. PMID: 21847651
Decatecholaminisation during sepsis.
Rudiger A, Singer M. Rudiger A, et al. Crit Care. 2016 Oct 4;20(1):309. doi: 10.1186/s13054-016-1488-x. Crit Care. 2016. PMID: 27716402 Free PMC article. No abstract available.
Sepsis, ghrelin, the cholinergic anti-inflammatory pathway, gut mucosal hyperpermeability, and high-mobility group box 1.
Fink MP. Fink MP. Crit Care Med. 2009 Aug;37(8):2483-5. doi: 10.1097/CCM.0b013e3181abf5f4. Crit Care Med. 2009. PMID: 19609124 No abstract available.
Esmolol for tight heart rate control in patients with STEMI: Design and rationale of the beta-blocker in acute myocardial infarction (BEAT-AMI) trial.
Er F, Erdmann E, Nia AM, Dahlem KM, Biesenbach E, Herrfurth T, Taghiyev Z, Le MT, Hellmich M, Kuhr K, Caglayan E, Gassanov N. Er F, et al. Int J Cardiol. 2015;190:351-2. doi: 10.1016/j.ijcard.2015.04.177. Epub 2015 Apr 23. Int J Cardiol. 2015. PMID: 25939126 Review. No abstract available.
Therapeutic synergy and complementarity for ischemia/reperfusion injury: β1-adrenergic blockade and phosphodiesterase-3 inhibition.
Huang MH, Poh KK, Tan HC, Welt FG, Lui CY. Huang MH, et al. Int J Cardiol. 2016 Jul 1;214:374-80. doi: 10.1016/j.ijcard.2016.03.200. Epub 2016 Apr 3. Int J Cardiol. 2016. PMID: 27085132 Review.

See all similar articles

Cited by

Gut and sublingual microvascular effect of esmolol during septic shock in a porcine model.
Jacquet-Lagrèze M, Allaouchiche B, Restagno D, Paquet C, Ayoub JY, Etienne J, Vandenesch F, Dauwalder O, Bonnet JM, Junot S. Jacquet-Lagrèze M, et al. Crit Care. 2015 Jun 4;19(1):241. doi: 10.1186/s13054-015-0960-3. Crit Care. 2015. PMID: 26041462 Free PMC article.

References

1. Lancet. 1992 Jan 25;339(8787):195-9 - PubMed
1. J Appl Physiol Respir Environ Exerc Physiol. 1984 Apr;56(4):1065-9 - PubMed
1. Arch Histol Cytol. 1995 Aug;58(3):303-6 - PubMed
1. Am J Respir Crit Care Med. 2004 Feb 15;169(4):525-33 - PubMed
1. Intensive Care Med. 2011 Nov;37(11):1849-56 - PubMed

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Ovid Technologies, Inc.
- Springer
Medical
- MedlinePlus Health Information